Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04377126 · ClinicalTrials.gov registry record · Phase 2
Unacylated Ghrelin to Improve Functioning in PAD
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT04377126 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 25 participants.
The verdict
NCT04377126, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
GIFT is a pilot, randomized, double-blinded clinical trial that will examine the effects of unacylated ghrelin on walking ability in people with peripheral artery disease (PAD) compared to placebo. Preliminary evidence suggests that unacylated ghrelin may improve blood flow to the extremities and promote improved skeletal muscle growth and energy use. A total of 30 participants with PAD will be randomized to one of two groups: unacylated ghrelin injections or placebo injections . Participants will self-administer the study drug or placebo subcutaneously once daily for four months. The primary outcome is change in six-minute walk distance between baseline and 4-month follow-up
Interventions
- DRUG Placebo
- DRUG Ghrelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-07-08 |
| Est. Completion | 2025-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04377126
The ClinicalTrials.gov registry entry for NCT04377126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04377126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04377126 about?
NCT04377126 is a clinical study titled "Unacylated Ghrelin to Improve Functioning in PAD". GIFT is a pilot, randomized, double-blinded clinical trial that will examine the effects of unacylated ghrelin on walking ability in people with peripheral artery disease (PAD) compared to placebo. Preliminary evidence suggests that unacylated ghrelin may improve blood flow to the extremities and pr...
What is the current status of trial NCT04377126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2020-07-08. Estimated completion is 2025-01-23.
What interventions are being tested in trial NCT04377126?
The interventions under investigation include: Placebo (DRUG), Ghrelin (DRUG).
Who is sponsoring clinical trial NCT04377126?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.